awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33400687-7C86BD6E-9704-46B6-A46A-0D0D8E824439
Q33400687-7C86BD6E-9704-46B6-A46A-0D0D8E824439
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33400687-7C86BD6E-9704-46B6-A46A-0D0D8E824439
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer
P2860
Q33400687-7C86BD6E-9704-46B6-A46A-0D0D8E824439
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33400687-7C86BD6E-9704-46B6-A46A-0D0D8E824439
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d8069a562e6007fd46b10935ed64316db8c58cde
P2860
Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints.